

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-May-2018  
Document Type: USP Monographs  
DocId: GUID-C97572D0-C294-4C6C-9C4C-E79155A126B0\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M29920\\_03\\_01](https://doi.org/10.31003/USPNF_M29920_03_01)  
DOI Ref: 1e1ve

© 2025 USPC  
Do not distribute

# Ergonovine Maleate Injection

» Ergonovine Maleate Injection is a sterile solution of Ergonovine Maleate in Water for Injection. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of  $C_{19}H_{23}N_3O_2 \cdot C_4H_4O_4$ .

**Packaging and storage**—Preserve in single-dose, light-resistant containers, preferably of Type I glass, and store in a cold place.

**USP REFERENCE STANDARDS (11)**—  
[USP Ergonovine Maleate RS](#)

**Identification**—The  $R_f$  value of the principal blue spot obtained from the *Test preparation* corresponds to that obtained from *Standard preparation A* in the chromatogram prepared as directed in the test for *Related alkaloids*.

**BACTERIAL ENDOTOXINS TEST (85)**—It contains not more than 700.0 USP Endotoxin Units per mg of ergonovine maleate.

**pH (791)**: between 2.7 and 3.5.

**Related alkaloids**— [NOTE—Conduct this test promptly, without exposure to daylight and with minimum exposure to artificial light.]

*Solvent mixture, Standard preparation, and Standard dilutions*—Prepare as directed in the test for [Related alkaloids](#) under [Ergonovine Maleate](#).

*Test preparation*—Immediately prior to use, transfer a volume of Injection, equivalent to about 5 mg of ergonovine maleate, to a separator, and extract with three 5-mL portions of chloroform. Discard the chloroform extracts. Render alkaline to litmus with 6 N ammonium hydroxide, and extract with three 5-mL portions of chloroform. Evaporate the combined extracts with the aid of a stream of nitrogen, but without heat, to dryness. Dissolve the residue so obtained in 0.5 mL of *Solvent mixture*.

*Procedure*—Proceed as directed for *Procedure* in the test for [Related alkaloids](#) under [Ergonovine Maleate](#).

**Other requirements**—It meets the requirements under [Injections and Implanted Drug Products \(1\)](#).

**Assay**—

*0.05 M Phosphate buffer*—Dissolve 6.8 g of monobasic potassium phosphate in 600 mL of water and adjust with phosphoric acid to a pH of 2.1. Dilute with water to 1000 mL, and mix.

*Mobile phase*—Prepare a suitable and degassed solution of *0.05 M Phosphate buffer* and acetonitrile (80:20) such that the retention time is approximately 3 minutes with a flow rate of 1 mL per minute.

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Ergonovine Maleate RS](#) in *Mobile phase*, adding sufficient water to equal 10% of the final volume, to obtain a solution having a known concentration of about 0.02 mg per mL.

*Assay preparation*—Quantitatively dilute an accurately measured volume of the Injection, equivalent to about 2 mg of ergonovine maleate, with *Mobile phase* and water, if necessary, to obtain a solution having a concentration of about 0.02 mg per mL in which the Injection volume plus any added water constitutes 10% of the final volume.

*Chromatographic system* (see [Chromatography \(621\)](#))—The liquid chromatograph is equipped with a 312-nm detector and a 3-mm × 30-cm column that contains packing L1. Chromatograph five replicate injections of the *Standard preparation*, and record the peak responses as directed under *Procedure*: the relative standard deviation is not more than 3.0%.

*Procedure*—By means of a suitable sampling valve, introduce equal volumes (about 100 µL) of the *Assay preparation* and the *Standard preparation* into the chromatograph. Measure the peak responses of Ergonovine Maleate, at corresponding retention times, obtained from the *Assay preparation* and the *Standard preparation*. Calculate the quantity, in mg, of  $C_{19}H_{23}N_3O_2 \cdot C_4H_4O_4$  in each mL of the Injection taken by the formula:

$$(CD/V)(r_U/r_S)$$

in which *C* is the concentration, in mg per mL, of [USP Ergonovine Maleate RS](#) in the *Standard preparation*, *V* is the volume, in mL, of Injection taken, *D* is the dilution factor, and  $r_U$  and  $r_S$  are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question               | Contact   | Expert Committee          |
|------------------------------|---|---------------------------|
| ERGONOVINE MALEATE INJECTION | <a href="#">Documentary Standards Support</a>                               | SM52020 Small Molecules 5 |
| REFERENCE STANDARD SUPPORT   | RS Technical Services<br><a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a> | SM52020 Small Molecules 5 |

Chromatographic Database Information: [Chromatographic Database](#)

---

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

**Current DocID:** GUID-C97572D0-C294-4C6C-9C4C-E79155A126B0\_3\_en-US

**Previous DocID:** GUID-C97572D0-C294-4C6C-9C4C-E79155A126B0\_1\_en-US

**DOI:** <https://doi.org/10.31003/USPNF.M29920.03.01>

**DOI ref:** [1e1ve](#)

OFFICIAL